Globus Medical FY2026 EPS Estimate Boosted by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Analysts at Zacks Research raised their FY2026 earnings per share estimates for shares of Globus Medical in a report issued on Tuesday, March 10th. Zacks Research analyst Team now expects that the medical device company will post earnings of $4.40 per share for the year, up from their prior forecast of $3.85. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2026 earnings at $1.37 EPS, Q1 2027 earnings at $1.07 EPS, Q2 2027 earnings at $1.14 EPS, Q3 2027 earnings at $1.21 EPS and FY2027 earnings at $4.66 EPS.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. The firm had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The firm’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.84 EPS.

A number of other analysts have also weighed in on the company. Needham & Company LLC increased their target price on Globus Medical from $112.00 to $114.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group upped their price target on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Royal Bank Of Canada raised their price target on shares of Globus Medical from $92.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Morgan Stanley lifted their price objective on shares of Globus Medical from $70.00 to $100.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Citigroup reissued a “market perform” rating on shares of Globus Medical in a research report on Thursday, January 8th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.36.

Globus Medical Trading Down 3.1%

GMED stock opened at $84.51 on Thursday. The stock has a market cap of $11.43 billion, a PE ratio of 21.45, a P/E/G ratio of 2.04 and a beta of 1.05. Globus Medical has a 12 month low of $51.79 and a 12 month high of $101.40. The company has a 50-day moving average price of $90.76 and a 200 day moving average price of $78.10.

Hedge Funds Weigh In On Globus Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. lifted its position in shares of Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Globus Medical by 2.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock worth $375,000 after buying an additional 170 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Globus Medical by 14.7% during the 3rd quarter. GAMMA Investing LLC now owns 1,438 shares of the medical device company’s stock worth $82,000 after acquiring an additional 184 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling

In other Globus Medical news, EVP Kelly Huller sold 20,000 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kyle Kline sold 3,594 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $363,353.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 35,594 shares of company stock valued at $3,332,253 over the last 90 days. Corporate insiders own 18.51% of the company’s stock.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised several near‑term and full‑year EPS estimates for GMED — including FY2026 to $4.40 (from $3.85) and FY2027 to $4.66 (from $4.16) — and lifted multiple quarterly forecasts (e.g., Q1 2027 to $1.07, Q2 2027 to $1.14, Q3 2027 to $1.21, Q4 2026 to $1.37). Zacks retains a “Strong‑Buy” rating, implying materially stronger earnings expectations than the current consensus (~$3.44).
• Positive Sentiment: The repeated upward revisions across quarters and fiscal years reinforce an improving earnings trajectory and could justify a higher multiple if revenue growth and margins hold — a supportive factor for medium‑term investors.
• Neutral Sentiment: Market commentary examines how Globus’s Q4 results and developments around competitor Nevro affect the investment thesis; this analysis may help investors assess risk/reward but does not itself change fundamentals. How The Globus Medical (GMED) Investment Story Is Evolving After Q4 Results And Nevro Update

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.